Lim Susan E, Ponamarev Mikhail V, Longley Matthew J, Copeland William C
Laboratory of Molecular Genetics, National Institute of Environmental Health Sciences, P.O. Box 12233, Research Triangle Park, NC 27709, USA.
J Mol Biol. 2003 May 23;329(1):45-57. doi: 10.1016/s0022-2836(03)00405-4.
Although antiviral nucleoside analog therapy successfully delays progression of HIV infection to AIDS, these drugs cause unwelcome side-effects by inducing mitochondrial toxicity. We and others have demonstrated that the mitochondrial polymerase, DNA polymerase gamma (pol gamma), participates in mitochondrial toxicity by incorporating these chain-terminating antiviral nucleotide analogs into DNA. Here, we explore the role of three highly conserved amino acid residues in the active site of human pol gamma that modulate selection of nucleotide analogs as substrates for incorporation. Sequence alignments, crystal structures and mutagenesis studies of family A DNA polymerases led us to change Tyr951 and Tyr955 in polymerase motif B to Phe and Ala, and Glu895 in polymerase motif A was changed to Ala. The mutant polymerases were tested for their ability to incorporate natural nucleotides and the five antiviral nucleoside analogs currently approved for antiviral therapy: AZT, ddC, D4T, 3TC and carbovir. Steady-state kinetic analysis of the pol gamma derivatives with the normal and antiviral nucleotides demonstrated that Tyr951 is largely responsible for the ability of pol gamma to incorporate dideoxynucleotides and D4T-MP. Mutation of Tyr951 to Phe renders the enzyme resistant to dideoxynucleotides and D4T-TP without compromising the activity of the polymerase. Alteration of Glu895 and Tyr955 to Ala had the largest effect on overall polymerase activity with normal nucleotides, producing dramatic increases in K(m(dNTP)) and large decreases in k(cat). Mutation of Tyr955 in pol gamma causes the degenerative disease progressive external ophthalmoplegia in humans, and we show that this residue partially accounts for the ability of pol gamma to incorporate D4T-MP and carbovir. Alteration of Glu895 to Ala slightly increased discrimination against dideoxynucleotides and D4T-TP. The mechanisms by which pol gamma selects certain nucleotide analogs are discussed.
尽管抗病毒核苷类似物疗法成功延缓了HIV感染向艾滋病的进展,但这些药物通过诱导线粒体毒性而产生不良副作用。我们和其他人已经证明,线粒体聚合酶,即DNA聚合酶γ(polγ),通过将这些链终止抗病毒核苷酸类似物掺入DNA而参与线粒体毒性。在这里,我们探讨了人类polγ活性位点中三个高度保守的氨基酸残基的作用,这些残基调节核苷酸类似物作为掺入底物的选择。A家族DNA聚合酶的序列比对、晶体结构和诱变研究使我们将聚合酶基序B中的Tyr951和Tyr955分别替换为Phe和Ala,并将聚合酶基序A中的Glu895替换为Ala。测试了突变聚合酶掺入天然核苷酸和目前批准用于抗病毒治疗的五种抗病毒核苷类似物的能力:齐多夫定(AZT)、双脱氧胞苷(ddC)、司他夫定(D4T)、拉米夫定(3TC)和卡波韦。对具有正常核苷酸和抗病毒核苷酸的polγ衍生物进行稳态动力学分析表明,Tyr951在很大程度上决定了polγ掺入双脱氧核苷酸和D4T-单磷酸(D4T-MP)的能力。将Tyr951突变为Phe使该酶对双脱氧核苷酸和D4T-三磷酸(D4T-TP)具有抗性,而不影响聚合酶的活性。将Glu895和Tyr955替换为Ala对正常核苷酸的总体聚合酶活性影响最大,导致米氏常数(K(m(dNTP)))显著增加,催化常数(k(cat))大幅降低。polγ中Tyr955的突变会导致人类患上退行性疾病进行性眼外肌麻痹,并且我们表明该残基部分解释了polγ掺入D4T-MP和卡波韦的能力。将Glu895替换为Ala略微增加了对双脱氧核苷酸和D4T-TP的辨别能力。讨论了polγ选择某些核苷酸类似物的机制。